Leukemia Research Reports最新文献

FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia 基于FLT3和NPM1 mRNA表达的新发急性髓系白血病风险分层。

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100494

Donghyun Kim , Grerk Sutamtewagul , Yeonhwa Yu

{"title":"FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia","authors":"Donghyun Kim , Grerk Sutamtewagul , Yeonhwa Yu","doi":"10.1016/j.lrr.2024.100494","DOIUrl":"10.1016/j.lrr.2024.100494","url":null,"abstract":"<div><div>Prognostication of acute myeloid leukemia (AML) at initial diagnosis relies on identification of pre-determined underlying genetic abnormalities. Nevertheless, the disease course of AML remains highly unpredictable and robust reliable prognostic biomarkers for newly diagnosed AML are lacking. We retrospectively explored two publicly available AML RNA-Seq datasets and found that inferior overall survival was associated with high-<em>FLT3</em> and low-<em>NPM1</em> transcript levels (“<em>FLT3</em><sup>high</sup>/<em>NPM1</em><sup>low</sup>”) compared to low-<em>FLT3</em> and high-<em>NPM1</em> transcript levels (“<em>FLT3</em><sup>low</sup>/<em>NPM1</em><sup>high</sup>”) in adult <em>de novo</em> AML patients, with a hazard ratio for death of at least 2. Transcript level-dependent differential overall survival was independent from the underlying <em>FLT3</em> or <em>NPM1</em> genotypes. Our two-gene RNA expression-based <em>de novo</em> AML risk stratification may supplement and fine-tune traditional genetic aberration-based prognostication methods.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100494"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100500

Gen Hasegawa , Noriharu Nakagawa , Yoshimichi Ueda , Masahide Yamazaki

引用次数: 0

Proteasome inhibitors prevent tumor cell proliferation in HHV-8-unrelated PEL-like lymphoma

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100497

Kiyotaka Kawauchi , Toshie Ogasawara

引用次数: 0

A rare case of CD38-negative abdominal multiple extramedullary plasmacytoma and literature review cd38阴性腹腔多发髓外浆细胞瘤1例并文献复习。

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100493

XS Bao, DH Gong, KG Zhou, W Huang

引用次数: 0

Retrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017–2019 2017-2019年美国工龄多发性骨髓瘤患者ASCT特征和费用的回顾性索赔数据分析。

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100496

Whanhui Chi , Juhyeon Song , Tyler J. Varisco

{"title":"Retrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017–2019","authors":"Whanhui Chi , Juhyeon Song , Tyler J. Varisco","doi":"10.1016/j.lrr.2024.100496","DOIUrl":"10.1016/j.lrr.2024.100496","url":null,"abstract":"<div><div>Multiple myeloma (MM) is a rare hematologic malignancy with a 5-year survival rate of 52 %. For transplant-eligible MM patients, high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is recommended. Given the complexities of the ASCT procedure, understanding patient-specific factors and their impact on treatment decisions is essential.</div><div>Our study examines patient characteristics and patterns of health resource utilization associated with ASCT receipt in patients with MM.</div><div>This retrospective study used the Merative™ MarketScan® database from 2017 to 2019 to analyze working-aged adults (18–65 years) with MM. We categorized 643 ASCT recipients by demographic characteristics (age, sex, region, employment status, year of ASCT procedure) and clinical factors (Charlson Comorbidity Index score). We assessed health resource utilization, focusing on ASCT-related costs, including total payments and hospitalization duration. Descriptive statistics were calculated for all variables, with means, medians, standard deviations for continuous variables, and frequencies for categorical variables. Pearson correlation assessed the relationship between total payment and hospitalization duration.</div><div>Over 80 % of patients were over 50, highlighting the need for age-specific clinical strategies. Most patients had CCI scores of 2–4, indicating a moderate comorbidity burden. The mean hospitalization duration was 21.71 days, with average ASCT costs totaling $166,235.99. The correlation coefficient of 0.21 indicated that total payments also increase as the number of hospitalization days increases.</div><div>These findings highlight the need for tailored care approaches and resource allocation in ASCT, informing future research and clinical decision-making.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100496"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When the mask slips: A peripheral T-cell lymphoma disguised as lupus with myelofibrosis in a patient with May-Hegglin syndrome 当面具滑落梅-赫格林综合征患者伪装成狼疮伴骨髓纤维化的外周 T 细胞淋巴瘤。

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100498

V Da Silva Constante , H Couvert , A Wolfromm , M Ilzkovitz

引用次数: 0

Targeting menin for precision therapy in high-risk acute myeloid leukemia 以 Menin 为靶点，对高风险急性髓性白血病进行精准治疗。

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100495

Abdur Jamil , Zaheer Qureshi , Zain Mary El-amir , Gillian Kupakuwana-Suk , Hamzah Akram , Mohsin Ahmad , Eric Huselton

引用次数: 0

Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report 慢性髓单细胞白血病合并罕见抗体患者的溶血性输血反应的处理：1例报告

IF 0.7

Leukemia Research Reports Pub Date : 2024-11-28 DOI: 10.1016/j.lrr.2024.100485

Grace S. Park , Himachandana Atluri , Courtney D. DiNardo , Bryan Guillroy , Jean Horak , Effrosyni Apostolidou , Maryam Buni , Guillermo Montalban Bravo , Naveen Pemmaraju

引用次数: 0

Acute lower limb ischemia revealing hypo granular acute promyelocytic leukemia 急性下肢缺血显示低颗粒急性早幼粒细胞白血病

IF 0.7

Leukemia Research Reports Pub Date : 2024-11-25 DOI: 10.1016/j.lrr.2024.100488

Sabrina Belmahi , Zainab Kajeiou , Loubna Yacoubi , Noussaiba Azzi , Mounia Slaoui , Abdelilah Berhili , Mohammed Bensalah , Rachid Seddik

{"title":"Acute lower limb ischemia revealing hypo granular acute promyelocytic leukemia","authors":"Sabrina Belmahi , Zainab Kajeiou , Loubna Yacoubi , Noussaiba Azzi , Mounia Slaoui , Abdelilah Berhili , Mohammed Bensalah , Rachid Seddik","doi":"10.1016/j.lrr.2024.100488","DOIUrl":"10.1016/j.lrr.2024.100488","url":null,"abstract":"<div><h3>Introduction</h3><div>Acute promyelocytic leukemia (AML-M3), classified as acute Myeloid leukemia with PML RARA according to the 5th edition of the World Health Organization classification of haematolymphoid tumors 2022 [1], is marked by abnormal promyelocyte proliferation and is known for high risks of bleeding and thromboembolic complications. We present a case where lower limb ischemia revealed this leukemia in a child.</div></div><div><h3>Case report</h3><div>An 11-year-old with minor ankle trauma developed severe lower limb ischemia, leading to the discovery of subtotal femoral artery thrombosis. Blood tests revealed hyperleukocytosis, thrombocytopenia, and anemia with 88 % blasts, confirming acute myeloid leukemia (AML-M3). Karyotyping showed a t(15;17) translocation, and the child was started on emergency chemotherapy.</div></div><div><h3>Discussion</h3><div>Acute promyelocytic leukemia (APL), classified as AML-M3 with PML-RARA, is characterized by abnormal promyelocytes and accounts for about 10 % of acute leukemias, mostly in middle-aged adults. It has two variants: common hypergranular and rare hypogranular forms. APL can present with bone marrow failure, anemia, bleeding, and occasionally thromboembolic events, as seen in this case. The ischemia mechanism is not fully understood but may involve vessel obstruction by blasts or hypercoagulability. Diagnosis relies on clinical, morphological, phenotypic, and cytogenetic evidence, with treatment involving all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).</div></div><div><h3>Conclusion</h3><div>Hypogranular acute promyelocytic leukemia (AML3v) is a rare form and is even rarer when it is discovered following an ischaemic event, which is what makes our case so special.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100488"},"PeriodicalIF":0.7,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country 越南骨髓增生异常肿瘤患者的治疗：在发展中国家的实践经验

IF 0.7

Leukemia Research Reports Pub Date : 2024-11-24 DOI: 10.1016/j.lrr.2024.100490

Quang Hao Nguyen , Minh Phuong Vu , Ha Trang Kieu , Duc Binh Vu , Ha Thanh Nguyen , Quoc Khanh Bach

{"title":"Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country","authors":"Quang Hao Nguyen , Minh Phuong Vu , Ha Trang Kieu , Duc Binh Vu , Ha Thanh Nguyen , Quoc Khanh Bach","doi":"10.1016/j.lrr.2024.100490","DOIUrl":"10.1016/j.lrr.2024.100490","url":null,"abstract":"<div><h3>Background</h3><div>Treatment of patients diagnosed with myelodysplastic neoplasms (MDS) is difficult and the outcome is still limited, especially in developing countries. We conducted this study in order to share some experience in treating patients diagnosed with MDS in developing countries.</div></div><div><h3>Methods</h3><div>This was a retrospective study that included 32 patients with newly MDS. 13 lower-risk patients, including 2 patients with MDS 5q- were treated with erythropoiesis stimulating agent (ESA). 19 patients with higher risk were treated with hypomethylating agent (HMA), which was decitabine.</div></div><div><h3>Results</h3><div>In the ESA treatment group, the rate of hematologic improvement-erythroid was 69.2 %, the rate of total hematologic improvement (with 3 lineages improvement) was 61.5 %. In the HMA treatment group, the overall response rate was 52.6 %. The follow-up times were 42 months. The overall survival (OS), leukemic transformation-free survival (LFS), and progression-free survival (PFS) of the ESA treatment group were 30.44, 28.91, and 28.29 months; respectively. The OS, LFS, and PFS of the HMA treatment group were 34.27, 31.45, and 26.83 months; respectively<strong>.</strong></div></div><div><h3>Conclusions</h3><div>Patients with lower risk MDS, including MDS 5q-, may benefit from treatment with erythropoiesis stimulating agent (ESA). Patients with higher risk MDS may have a favorable outcome with decitabine (HMA) treatment.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100490"},"PeriodicalIF":0.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0